ProfileGDS5678 / 1416164_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 88% 85% 91% 84% 88% 87% 87% 89% 91% 90% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8648288
GSM967853U87-EV human glioblastoma xenograft - Control 26.6902187
GSM967854U87-EV human glioblastoma xenograft - Control 36.8177288
GSM967855U87-EV human glioblastoma xenograft - Control 46.5124785
GSM967856U87-EV human glioblastoma xenograft - Control 57.396891
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0604684
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6644788
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5674587
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6212887
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0045389
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3925691
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2028790
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8620188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8553488